Intellia Therapeutics: Is This Gene Editing Stock Positioned for a Comeback?

Investing in early-stage innovation stocks can be challenging, especially with short-sellers often targeting them before pivotal events. This can cause stock prices to plummet. Such downturns might last for years while companies work on significant product developments and navigate regulatory challenges. However, the momentum can shift rapidly once these firms hit crucial milestones.

Intellia Therapeutics (NASDAQ: NTLA), known for its groundbreaking gene editing technology, has seen its shares decline by more than 84% in the past 36 months. Yet, equity analyst Rachel Elfman from Morningstar suggests that the market might be undervaluing Intellia’s innovative pipeline. Other analysts on Wall Street also share a positive outlook, setting a consensus price target of $67.50 for the company, which indicates a staggering potential upside of 234% from current prices.

Image source: Getty Images.

What factors are fueling this optimism about Intellia? Understanding the company’s pipeline improvements, financial health, and potential challenges is essential for investors considering this underperforming stock in the biotech sector.

Pivotal Pipeline Developments

One of Intellia’s leading candidates, NTLA-2001 (also referred to as nexiguran ziclumeran or “nex-z”), is making significant progress in late-stage trials for transthyretin (ATTR) amyloidosis. Furthermore, Intellia plans to initiate a Phase 3 trial for hereditary ATTR amyloidosis with polyneuropathy by the year’s end, expanding its clinical program ambitiously.

Additionally, the company’s program NTLA-2002, targeting hereditary angioedema (HAE), has recently shown promising Phase 2 results, compelling Intellia to move this program to a pivotal Phase 3 trial. This advancement in late-stage projects indicates notable progress in Intellia’s clinical strategy.

Strong Financials Support Growth Plans

Intellia’s solid financial standing, with $939.9 million in cash as of the second quarter of 2024, provides a buffer for its ambitious clinical development goals. With financial resources estimated to last until late 2026, the company can continue advancing its pipeline without immediate funding worries.

While the company faces high research and development costs linked to ongoing trials, Intellia is effectively mitigating expenses through collaborations. Notably, its partnership with Regeneron Pharmaceuticals for NTLA-2001 allows Intellia to keep 75% of potential future profits while sharing some development costs.

The Risks of Investing in Innovative Biotech

Investing in Intellia Therapeutics comes with high stakes. As a clinical-stage biotech company lacking approved products, Intellia must navigate substantial regulatory obstacles and intrinsic development risks. However, the potential benefits are equally considerable. Intellia’s CRISPR/Cas9 gene editing platform could pave the way for effective and transformative treatments for rare genetic disorders that currently have few options available.

Rachel Elfman estimates a 35% to 40% chance of regulatory approval for Intellia’s lead programs. This assessment highlights the inherent risks but also hints at the exciting prospects if the therapies receive approval.

Intellia’s focus on rare diseases, such as ATTR amyloidosis and HAE, could be a clever strategic move, given the growing need for effective treatment options in these areas despite a limited current offering.

If Intellia secures regulatory approvals for its gene editing solutions, they may provide more efficient treatment options and capture significant market share in niche areas. This could lead to substantial revenue streams in the next five years.

Is It Time to Invest in Intellia?

As a frontrunner in gene editing technology, Intellia presents intriguing potential for investors looking to tap into groundbreaking therapeutic developments. The company’s success in advancing multiple candidates to late-stage trials, coupled with a strong financial status, makes it an attractive consideration for high-risk, high-reward investment strategies in the biotechnology arena.

However, the transition from promising trial results to successful commercialization comes with numerous challenges. Intellia’s candidates may encounter unforeseen issues during clinical trials, regulatory evaluations, or market launches.

Moreover, significant short-seller activity—almost 15% of outstanding shares sold short as of September 30, 2024—highlights these risks and suggests potential volatility in stock prices.

To conclude, whether to invest in Intellia largely depends on an individual’s belief in the revolutionary potential of gene editing technology. For those confident that CRISPR-based therapies will transform medicine, the current valuation of Intellia could represent an exceptional investment opportunity.

Investors should, however, prepare for a turbulent journey as the company continues to navigate the complex terrain of clinical trials, regulatory approvals, and market entry. With its promising pipeline and significant upside potential, Intellia embodies the inherent risks and rewards associated with pioneering biotechnology investments.

Should You Invest $1,000 in Intellia Therapeutics Right Now?

Before purchasing shares of Intellia Therapeutics, consider the following:

The Motley Fool Stock Advisor analyst team recently identified what they believe are the 10 best stocks for investors to buy now, excluding Intellia from this list. Those selected stocks could generate substantial returns in the years ahead.

Recall when Nvidia was featured on this list on April 15, 2005… an investment of $1,000 back then would now be worth $806,459!*

Stock Advisor offers investors a straightforward guide to success, including strategy tips for building a portfolio, regular updates from analysts, and two new stock picks each month. Since its inception in 2002, the Stock Advisor service has significantly outperformed the S&P 500, quadrupling its returns.

See the 10 stocks »

*Stock Advisor returns as of October 14, 2024

George Budwell holds no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Intellia Therapeutics. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.